The COVID-19 pandemic has caused great devastation throughout the world, and effective solutions to clinically detect the virus are urgently needed. While the qRT-PCR method is useful for detecting the presence of SARS-CoV-2 virus in people, it is useful only for confirming recent and active infections. SARS-CoV-2 detection through the use of antibody-based serological assays is a sensitive and useful method that allows for the diagnosis of infected individuals and population surveillance. Antibody tests can tell us who has had the disease, including asymptomatic individuals and people who only exhibited minor symptoms. These tests also allow us to quantify the number of people who have been infected, the number of deaths due to this disease, as well as the level of herd immunity in the population.
In working towards developing a COVID-19 antibody testing solution, we combined the unique advantages of GenScript's MonoRab™ service and the Beacon single cell sorting platform to generate high quality, highly diverse rabbit monoclonal antibodies (mAbs) towards the SARS-CoV-2 RBD domain. Rabbits are able to generate highly diverse antibodies against antigens normally non-immunogenic in mice, with up to 100 fold higher affinity for their target antigen compared to mouse. In just 24 hours, we completed immunized rabbit processing, immune cell isolation and enrichment, single cell sorting, on-chip binding and blocking screening, a process that would have otherwise taken three months using the traditional hybridoma method. The anti-RBD rabbit mAbs we have generated have high affinity and specificity, with some clones displaying pseudovirus neutralizing activity.
In this webinar you will learn:
- An overview of rabbit monoclonal antibodies
- Technologies for rabbit monoclonal antibody preparation
- Case study for COVID-19 antibody development
- GenScript's Beacon-based antibody generation service
Pei Liu graduated from Nanjing University with a PhD in Pharmacy. She joined GenScript in 2019 and serves as a Senior Scientist with the Antibody Department. She is mainly engaged in antibody development and establishment of the Beacon single B cell antibody discovery platform. In addition, she has worked on many different types of research projects and has a wealth of experience in ELISA kit development.